Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Sarda Proteins Ltd
| Standalone Audited Financial Results for the Quarter and Financial Year Ended March 31, 2026
Report Source
⬤30th Apr 26
Summary : Sarda Proteins reported significant profit growth for FY26, driven by a large advance against equity, though its allotment is pending, and operating cash flow is negative.
Quarterly Report Analysis & Insights
Financial Disclosures
- Cost of Material Consumed: Rs. 1,547.83 Lakhs (FY26)
- Employee Benefit Expenses: Rs. 3.00 Lakhs (FY26)
- Other expenses: Rs. 36.01 Lakhs (FY26)
- Revenue from operations: Rs. 1,615.84 Lakhs (FY26)
- Other Income: Rs. 34.85 Lakhs (FY26)
- Net cash from operating activities: (Rs. 7,638.85) Lakhs (FY26)
- Net cash from financing activities: Rs. 8,350.50 Lakhs (FY26)
- Net increase in cash and cash equivalents: Rs. 747.59 Lakhs (FY26)
- Total Assets increased significantly to Rs. 8,661.06 Lakhs (FY26) from Rs. 264.81 Lakhs (FY25)
- Current Assets driven by Rs. 7,463.14 Lakhs in 'Others (Advances)'
- Current Liabilities include Rs. 8,337.50 Lakhs for 'Advance against Equity'
- Standalone financial results only.
Corporate Overview
- Renewable Energy Sector Solar Module Products
- Renewable Energy Sector Solar Module Products
Risk Factors
- Equity share allotment remains pending.
- Operating cash flow is negative.
- High reliance on other advances.
- Single business segment concentration.
Key Drivers
- Profit for period significantly increased.
- Substantial advance received for equity.
- Unmodified audit opinion received.
- Focus on renewable energy products.
Auditor’s Report
- Unmodified opinion on standalone financial results.
- Advance Against Equity Share of Rs. 8337.50 Lakhs pending allotment.
Board Commentary
- Received Rs. 8337.50 Lakhs as Advance Against Equity Share, allotment pending.